Lifecare ASA

Regulatory Filings • Sep 24, 2025

Lifecare strengthens miniaturisation roadmap with new patent applications

Lifecare strengthens miniaturisation roadmap with new patent applications

Bergen, Norway, 24 September 2025 -- Lifecare ASA (LIFE), a MedTech company

developing next-generation continuous glucose monitoring (CGM) technology,

announces that new patent applications have been filed in Europe and the

United States related to surface acoustic wave (SAW) sensing for osmotic

glucose measurement.

SAW sensors are tiny chips that detect extremely small surface vibrations and

are already widely used in other industries. When combined with Lifecare's

proprietary osmotic principle -- where glucose levels are reflected as

pressure changes -- SAW sensors provide an additional way to measure these

changes in very small devices.

This technology strengthens Lifecare's roadmap towards further miniaturisation

of implantable sensors. The company's first product generation is based on

proven, commercially available piezoresistive pressure sensors, ensuring size,

reliability, and manufacturability for today's needs.

Alongside Lifecare's licensed Nano Tunneling Resistor (NTR) technology, SAW

represents an alternative option for future miniaturisation -- with the

potential to improve sensitivity while supporting standardised production

methods for faster development.

The patent applications have been filed by Lifecare's academic partner Johann

Wolfgang Goethe University Frankfurt, under a framework that grants Lifecare

defined R&D rights and an option to secure commercial rights. The European

application (EP 4 619 744) is scheduled for publication in the European Patent

Bulletin on 24 September 2025.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring ("CGM") systems to market.

Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor

technology is suitable for identifying and monitoring the occurrence of a wide

range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42